These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31674150)

  • 1. Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development.
    Ahmed MA; Patel C; Drezner N; Helms W; Tan W; Stypinski D
    Clin Transl Sci; 2020 Jan; 13(1):31-40. PubMed ID: 31674150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reviewing the role of healthy volunteer studies in drug development.
    Karakunnel JJ; Bui N; Palaniappan L; Schmidt KT; Mahaffey KW; Morrison B; Figg WD; Kummar S
    J Transl Med; 2018 Dec; 16(1):336. PubMed ID: 30509294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical development of new drugs. Safety of clinical trials in healthy volunteers].
    Dal-Ré R
    Med Clin (Barc); 2016 Aug; 147(4):154-6. PubMed ID: 27157790
    [No Abstract]   [Full Text] [Related]  

  • 6. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Am Soc Clin Oncol Educ Book; 2015; ():3-8. PubMed ID: 25993134
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I clinical trials of anticancer drugs in healthy volunteers: need for critical consideration.
    Gupta P; Gupta V; Gupta YK
    Indian J Pharmacol; 2012; 44(4):540-2. PubMed ID: 23087528
    [No Abstract]   [Full Text] [Related]  

  • 8. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthy volunteers in first-in-human oncology drug development for small molecules.
    de Las Heras B; Bouyoucef-Cherchalli D; Reeve L; Reichl A; Mandarino D; Flach S; Vidal L; van Brummelen EMJ; Steeghs N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1773-1784. PubMed ID: 34558113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical Trials.
    Young TC; Srinivasan S; Vetter ML; Sethuraman V; Bhagwagar Z; Zwirtes R; Narasimhan P; Chuang T; Smyth BJ
    J Clin Pharmacol; 2017 Sep; 57(9):1079-1087. PubMed ID: 28510323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the institutional submission and approval process for clinical research protocols in oncology.
    Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R
    J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical designs for Phase I combination studies in oncology.
    Wages NA; Ivanova A; Marchenko O
    J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C; Lee JJ; Siu LL
    J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
    Farha M; Masson E; Tomkinson H; Mugundu G
    J Clin Pharmacol; 2019 Apr; 59(4):463-471. PubMed ID: 30536979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unveiling changes in the landscape of patient populations in cancer early drug development.
    Hierro C; Azaro A; Argilés G; Elez E; Gómez P; Carles J; Rodon J
    Oncotarget; 2017 Feb; 8(8):14158-14172. PubMed ID: 27835915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
    Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
    Postel-Vinay S; Massard C; Soria JC
    Eur J Cancer; 2020 Sep; 137():235-239. PubMed ID: 32805640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New requirements for phase I trials: a challenge for Italian clinical research.
    Marchesi E; Monti M; Nanni O; Bassi L; Piccinni-Leopardi M; Cagnazzo C
    Tumori; 2018; 104(1):15-21. PubMed ID: 28799641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals?
    Balducci L
    Cancer Control; 2015 Apr; 22(2):232-4. PubMed ID: 26068770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.